1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Morocco Pharmaceuticals and Healthcare Report Q1 2017

Morocco Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 92 pages

Includes 3 FREE quarterly updates

BMI View:
We uphold our view that Morocco's pharmaceutical market will become more attractive for multinational drugmakers to invest in. As part of a wider bid to stimulate industrial development in Morocco, the domestic pharmaceutical industry will be given a significant boost as plans to strengthen local manufacturing capabilities come into fruition. The Moroccan government is also committed to improving the country's regulatory system and issues surrounding corruption. However, an uncertain drugpricing environment - a result of price cuts and tax hikes on medicines - will be an issue for potential investors in the market.

Headline Expenditure Projections


- Pharmaceuticals: MAD13.39bn (USD1.37bn) in 2015 to MAD14.19bn (USD1.45bn) in 2016; +6.0% in local currency terms and +5.6% in US dollar terms. Forecast revised downwards in local currency terms from last quarter.

- Healthcare: MAD56.70bn (USD5.81bn) in 2015 to MAD59.51bn (USD6.08bn) in 2016; +5.0% in local currency terms and +4.5% in US dollar terms. Forecast revised upwards from last quarter. Morocco is viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region. In our Q117 proprietary Pharmaceutical Risk/Reward Index (RRI) table, Morocco is ranked as the 12th most attractive market in the region out of the 33 countries assessed. The country scores 46.2 out of 100, maintaining its score from last quarter.

Table Of Contents

Morocco Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Morocco 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 26
OTC Medicines Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2014-2020) 31
Pharmaceuticals and Healthcare Risk/Reward Index 32
Middle East and Africa Risk/Reward Index - Q1 2017 32
Morocco Risk/ Reward Index 40
Rewards 40
Risks 41
Regulatory Review 42
Intellectual Property Issues 43
Pricing Regime 43
Reimbursement Regime 46
Market Overview 49
Healthcare Sector 49
Table: Healthcare Resources (Morocco 2010-2015) 53
Table: Healthcare Personnel (Morocco 2010-2015) 53
Table: Healthcare Activity (Morocco 2010-2015) 54
Research and Development 58
Clinical Trials 58
Epidemiology 59
Competitive Landscape 62
Research-Based Industry 62
Table: Members Of MIS (2011) 62
Table: Members Of AMIP (2011) 63
Table: Multinational Market Activity 63
Generic Drugmakers 63
Pharmaceutical Distribution 66
Pharmaceutical Retail Sector 67
Company Profile 68
GlaxoSmithKline 68
Laprophan 70
Pfizer 73
Sanofi 76
Sothema 79
Demographic Forecast 81
Demographic Outlook 81
Table: Population Headline Indicators (Morocco 1990-2025) 82
Table: Key Population Ratios (Morocco 1990-2025) 82
Table: Urban/Rural Population and Life Expectancy (Morocco 1990-2025) 83
Table: Population By Age Group (Morocco 1990-2025) 83
Table: Population By Age Group % (Morocco 1990-2025) 84
Glossary 86
Methodology 88
Pharmaceutical Expenditure Forecast Model 88
Healthcare Expenditure Forecast Model 88
Notes On Methodology 89
Risk/Reward Index Methodology 90
Index Overview 91
Table: Pharmaceutical Risk/Reward Index Indicators 91
Indicator Weightings 92

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.